BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Sep. 5, 2016
View Archived Issues
Apixaban equivalent to warfarin in AF patients with cancer
Read More
Seattle Genetics initiates phase I study of SGN-CD123A for relapsed/refractory AML
Read More
Galenica completes acquisition of Relypsa
Read More
BioPontis Alliance for Rare Diseases and VIB enter a strategic partnership
Read More
Merck & Co. discontinues development of odanacatib for osteoporosis
Read More
Novartis describes discovery of novel PI3Kdelta inhibitor CDZ-173
Read More
Allergan studies oral ubrogepant for acute treatment of migraine in phase III
Read More
Opsona Therapeutics' OPN-305 granted FDA orphan drug status
Read More
GSK initiates phase IIa trial of shigella vaccine in Kenya
Read More
ASLAN Pharmaceuticals licenses RON antibody from A*STAR
Read More
Amgen obtains global rights to BI-836908 from Boehringer Ingelheim
Read More
CADPA biomarker algorithm identifies asymptomatic patients at risk for cardiac events
Read More
NIH funds six projects seeking to identify biological factors that influence neural regeneration
Read More
Central administration of donepezil improves long-term heart failure prognosis in vivo
Read More
Dynavax provides update on recent dialogue with FDA regarding Heplisav-B BLA
Read More
Glucox Biotech describes novel NADPH oxidase 4 inhibitors
Read More
Bayer Pharma patents Wnt signaling pathway inhibitors
Read More
FDA extends IDegLira NDA review
Read More
GenSight Biologics' GS-030 receives orphan drug designation and ATMP classification in Europe
Read More
Suzhou Zelgen Biosciences presents new farnesoid X receptor agonists
Read More
Shanghai De Novo Pharmatech identifies novel IDO1/TDO2 inhibitors
Read More
Guangzhou Institutes of Biomedicine and Health divulges UCP 1 activators
Read More
New phase II trial assesses CD24Fc for prevention of GvHD
Read More
Jiangsu Hengrui Medicine, Shanghai Hengrui Pharmaceutical generate anti-HER2 antibody-drug conjugate
Read More
Genentech reports positive results from phase III OAK study of atezolizumab
Read More
New class of FBPase 1 inhibitors identified at Chinese Academy of Medical Sciences
Read More